April 22, 2020: We commend the assessment of the potential benefits and harms of electrocardiography screening among asymptomatic adults. Furthermore, we applaud the commitment to assessing these potential benefits and harms by subgroups defined by stroke risk, as well as by race/ethnicity, age, and sex.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
National Center for Health Research’s Public Comments on Simplifying Meal Service and Monitoring Requirements in the National School Lunch and School Breakfast Programs
The recently proposed changes would drastically weaken school nutrition by creating large loopholes in school nutrition requirements. Despite claiming that the goal is to offer “greater ability to offer wholesome, nutritious, and appealing meals to students,” the result of these guidelines would be to seriously harm children’s access to healthy food options. Therefore, we strongly disagree with the proposed changes to school nutrition requirements.
Read More »NCHR Support for IG Removal Protections
April 10, 2020. NCHR signed on to this letter to express our grave and urgent concern for the independence of federal inspectors general.
Read More »NCHR’s Comments on FDA’s Information Collection Activities on Abuse Deterrent Formulations
April 6, 2020: We support FDA’s decision to conduct a comprehensive evaluation of opioid prescribers’ knowledge, attitudes, perceptions, experiences and behaviors related to Abuse Deterrent Formulations (ADF) and agree with the FDA that new language is needed to better describe and explain ADF.
Read More »NCHR’s Comments on FDA’s Draft Guidance on Levonorgestrel
March 23, 2020: A diverse participant population is necessary for the results to be relevant to women of different races, ethnicities, and BMI.
Read More »